Strength in Numbers

Patients facing a cancer diagnosis invariably have many questions, but one tops the list – what is the best treatment? Answering that question is the compelling goal of medical research that is testing new treatments for similarly-diagnosed patients in carefully monitored and controlled ways.

More >>
 
CCTG IND234 prostate precision medicine trial - Dr. Kim Chi

Innovative study advances personalized medicine for prostate cancer patients

CCTG IND224 is a new clinical trial, opening across Canada, is considered a major advancement in precision medicine for prostate cancer and the first of its kind in the world.

More >>
 
CCTG LY16 | RELEVANCE published in New England Journal of Medicine

CCTG LY16 | RELEVANCE published in New England Journal of Medicine

The results of the CCTG LY16 trial of Rituxmab plus Lenalidomide in Advanced Untreated Follicular Lymphoma (RELEVANCE), recently published in New England Journal of Medicine, has the potential to offer a new treatment option to lymphoma patients, that does not require chemotherapy.

More >>
 
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 

Planned trials

ALC5

Novel Therapeutics vs Azacitidine in Patients with AML or High Risk Myelodysplastic Syndrome, Aged 60 or Older (LEAP, Intergroup Less Intense AML Platform Trial)

More >>

CRC9

Circulating Tumor DNA as a Predictive Marker for Response to Chemotherapy in Pts with Stage II Colon Ca

ENC1

Carboplatin & Paclitaxel with or without Pembrolizumab for Measurable Stage 3 or 4A, Stage 4B or Recurrent Endometrial Cancer

More >>

HDC1

Nivolumab or Brentuximab Vedotin plus AVD in Pts (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

More >>

LY18

A Phase I Master Protocol of Novel Combination Therapy for Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma

More >>

MAC25

Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2 Positive Metastatic Cancer

More >>

Recently activated

ALC6

Efficacy of the Addition of Inotuzumab Ozogamicin to Frontline Therapy in Young Adults with Precursor B-Cell ALL

More >>

BRC7

INSIGNA: Firstline Immunotherapy alone or in Combination with Chemo in Induction/Maintenance or Post Progression in Adv NSCLC with Immunobiomarker SIGNature-driven Analysis

More >>

HNC2

Radiotherapy with Concurrent MEDI4736 vs Radiotherapy with Concurrent Cetuximab in Pts with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin

More >>

I238

Durvalumab Retreatment in Patients who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity

More >>

MAC26

Testing the Addition of the Study Drug Olaparib to the Usual Radiotherapy in Inflammatory Breast Cancer Patients

More >>

PR20

Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer [PLATON]

More >>
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 
TAILORx / MAC.12 breast cancer trial showed no benefit from chemotherapy for 70% of women with the most common form of breast cancer.

TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancer

Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.

More >>
 

Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide

Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.

More >>
 
Award recipients

Canadian Cancer Research Alliance announces award winners

Canadian Cancer Research Alliance has announced the recipients of their 2017 awards: former CCTG Director, Dr. Elizabeth Eisenhauer will recieve the Exceptional Leadership in Cancer Research award and Ms. Judy Needham will receive the Exceptional Leadership in Patient Involvement in Cancer award.

More >>
 

Publications

Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: a randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219 (ONLINE)

Lung Cancer , 2019
Melosky B;Bradbury P;Tu D;Florescu M;Reiman A;Nicholas G;Basappa N;Rothenstein J;Goffin JR;Laurie SA;Wheatley-Price P;Leighl N;Goss G;Reaume MN;Butts C;Murray N;Card C;Ko J;Blais N;Gray S;Lui H;Brown-Walker P;Kaurah P;Prentice LM;Seymour L;

More >>

RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis

J Clin Oncol 37: 1102 - 1110, 2019
Litiere S;Isaac G;de Vries EGE;Bogaerts J;Chen A;Dancey J;Ford R;Gwyther S;Hoekstra O;Huang E;Lin N;Liu Y;Mandrekar S;Schwartz LH;Shankar L;Therasse P;Seymour L;

More >>

CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC)

J Clin Oncol 37, 2019
Chen EX;Jonker DJ;Kennecke HF;Berry SR;Couture F;Ahmad CE;Goffin JR;Kavan P;Harb M;Colwell B;Samimi S;Samson B;Abbas T;Aucoin N;Aubin F;Koski SL;Wei AC;Magoski NM;Tu D;O'Callaghan CJ;

More >>

LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/ Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer

Clin Lung Cancer 20: 66 - 73, 2019
Seymour L;Le Teuff G;Brambilla E;Shepherd FA;Soria JC;Kratzke R;Graziano S;Douillard JY;Rosell R;Reiman A;Lacas B;Lueza B;viel-Ronen S;McLeer A;Le Chevalier T;Pirker R;Filipits M;Dunant A;Pignon JP;Tsao MS;

More >>

Outcomes of Older Patients(>= 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20

Clinical Colorectal Cancer 18: e140 - e149, 2019
Wells JC;Tu D;Siu LL;Shapiro JD;Jonker DJ;Karapetis CS;Simes J;Liu G;Price TJ;Tebbutt NC;O'Callaghan CJ;

More >>

Pilot study of the ability to probabilistically link clinical trial patients to administrative data and determine long-term outcomes

Clinical Trials 16: 14 - 17, 2019
Hay AE;Pater JL;Corn E;Han L;Camacho X;O'Callaghan C;Chong N;Bell EN;Tu D;Earle CC;

More >>

Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis (ONLINE)

Leuk Lymphoma : 1 - 8, 2019
Al-Mansour Z;Cook JR;Constine LS;Couban S;Stewart DA;Shea TC;Porcu P;Winter JN;Kahl BS;Smith SM;Marcellus DC;Barton KP;Mills GM;LeBlanc M;Rimsza LM;Forman SJ;Leonard JP;Fisher RI;Friedberg JW;Stiff PJ;

More >>

Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218

Pediatr Blood Cancer 66: e27540, 2019
Deyell RJ;Wu B;Rassekh SR;Tu D;Samson Y;Fleming A;Bouffet E;Sun X;Powers J;Seymour L;Baruchel S;Morgenstern DA;

More >>